The high level of controversy and media furore over diabetic drug Avandia has led many physicians and healthcare professionals to question the way in which drugs are approved in the America .
Avandia, the drug for diabetics at the heart of concerns, was approved by the Food and Drug Administration in 1999. It has generated about $3 billion in revenue per annum for the company that manufactures it, GlaxoSmithKline. Physicians are now questioning whether Avandia should ever have been approved.
Clifford J. Rose, a leading endocrinologist in American, reportedly commented: “[Avandia] got on the market quickly, It sold a billion a year or more. It was really expensive drug, and I think the expectations were huge. The concern is if we’re going to put somebody on a drug for a long period of time, we’d better make sure it’s safe.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…